Study to Evaluate How Human Secretin Injection Affects Pancreatic Fluid in Healthy Adults Undergoing Endoscopic Ultrasound

What this Trial Is About

Researchers are studying the effects of human secretin injection on the composition of pancreatic fluid in healthy adults. The study focuses on collecting pancreatic fluid from the duodenum after stimulation by secretin to better understand pancreatic function. Healthy volunteers aged 18 to 80 without pancreatic disease are being evaluated in this phase 4, open-label study. Participants receive an intravenous dose of human synthetic secretin 0.2 micrograms per kilogram during an endoscopic ultrasound procedure performed for non-pancreatic reasons. Pancreatic fluid is collected at 5, 10, 15, and 20 minutes after secretin administration by aspirating duodenal fluid through the echoendoscope. This single-group study aims to observe changes in pancreatic fluid composition at these time points. During the study, participants undergo an endoscopic ultrasound with secretin stimulation and fluid collection. Researchers measure bicarbonate, sodium, potassium, and chloride levels in the pancreatic fluid at each collection time. The trial monitors the pancreatic fluid composition to understand secretins effect, with no masking or placebo. Participation lasts for the procedure and fluid collection, with the primary outcome measured shortly after secretin administration.

A Study Of Effect Of Secretin For In Injection (Chirostim) On Pancreatic Fluid Composition In Healthy Subjects